Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Xintela AB (1XT) Stock Price & Analysis

1XT Stock Chart & Stats

€0.01€0.00(0.00%)
At close: 5:30 PM GMT+2
EUR 0.01EUR 0.012EUR 0.01413 Apr10 Jun
Day’s Range
EUR 0.01 - EUR 0.01
52-Week Range
EUR 0.01 - EUR 0.05
Previous Close
EUR 0.01
Volume
0
Average Volume (3M)
1,089
Market Cap
EUR 12.20M
Enterprise Value
EUR 172.39M
Total Cash (Recent Filing)
EUR 30.72M
Total Debt (Recent Filing)
EUR 30.00M
Price to Earnings (P/E)
―
Beta
0.56
Next Earnings
Nov 27, 2026 (Est.)
EPS Estimate
0
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused ITGA10 Platform

A focused platform around ITGA10 gives Xintela a coherent scientific identity across two medical applications. Reusing the same receptor expertise in cell therapies and antibodies may improve research leverage and create multiple routes to commercial value over the next several quarters.

Strong Gross Margin And Revenue Growth

Revenue growth alongside an approximately 82% gross margin indicates that the existing revenue base has favorable underlying economics, even though scale is currently limited. If growth continues, this margin profile could provide a stronger foundation for funding development and expanding operating leverage.

Partnership-led Monetization Model

The intended monetization model offers several potential paths to capture value from the ITGA10 platform, including licensing, milestones, royalties, and collaborations. Partnering can help convert scientific assets into commercial opportunities while reducing the need to commercialize every program independently.

Bears Say

Severe And Persistent Losses

The scale of losses relative to revenue shows that the current operating structure is far from self-sustaining. Persistent negative EBIT, EBITDA, and net income reduce internal funding capacity and mean that meaningful progress depends on future revenue growth, partnering proceeds, or additional financing.

Heavy Cash Burn

Large negative operating and free cash flow indicates that Xintela consumes substantial cash to support its activities without generating sufficient cash internally. The deterioration in free cash flow suggests funding pressure is not yet easing, increasing reliance on external capital over the coming quarters.

Weak Solvency And Capital Structure

Negative equity combined with meaningful debt represents a materially weakened capital base and limits financial flexibility. Cumulative losses have eroded prior equity, while leverage increases dependence on external funding and may constrain the company’s ability to absorb setbacks or finance development on favorable terms.

Xintela AB News

1XT FAQ

What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is €12.20M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s next earnings report is estimated for Nov 27, 2026 (not yet confirmed), which is in 26 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on Aug 28, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Xintela AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is 0.00.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in DE:1XT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology